

Resource Summary Report

Generated by [ASWG](#) on Aug 2, 2026

PIDD

RRID:SCR_007854

Type: Tool

Proper Citation

PIDD (RRID:SCR_007854)

Resource Information

URL: https://www.oxfordjournals.org/our_journals/nar/database/summary/954

Proper Citation: PIDD (RRID:SCR_007854)

Description: THIS RESOURCE IS NO LONGER IN SERVICE, documented August 19, 2016. A database for the study of protein inter-atomic distance distribution. Currently, the distances are extracted from the protein structures determined through X-ray Crystallography, but they could also be obtained from NMR structural models. The known structures with the resolution higher than 2Å and less than 70% sequence similarities are selected. Each type of distances is specified in terms of the types of the atoms it involves, the types of the residues containing the atoms, and the types of the residues in between the two end residues in sequence. An automated system is built to generate and process the data dynamically. The system consists of two levels of databases. The first one stores the sequence and structure information for a large set of high-resolution protein structures, with a similar data structure as the structural data represented in the PDB Data Bank. The second one stores the information for the distance distributions, with each record corresponding to a distribution function. The second database is built dynamically from the first one. The database can provide structural information in terms of distance distributions to structural biologists. Such information can be valuable for the study of many fundamental biological problems including protein structure prediction and determination, protein dynamics simulation, molecular design, protein structural analysis and classification, etc.

Abbreviations: PIDD

Synonyms: Protein Inter-Atomic Distance Distribution Database

Resource Type: data or information resource, database

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: PIDD

Resource ID: SCR_007854

Alternate IDs: nif-0000-03287

Old URLs: <http://pidd.math.iastate.edu>

Record Creation Time: 20220129T080244+0000

Record Last Update: 20260801T190948+0000

Ratings and Alerts

No rating or validation information has been found for PIDD.

No alerts have been found for PIDD.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Chellappan D, et al. (2025) Generalizability of machine learning models for diabetes detection a study with nordic islet transplant and PIMA datasets. Scientific reports, 15(1), 4479.

Shams MY, et al. (2025) A novel RFE-GRU model for diabetes classification using PIMA Indian dataset. Scientific reports, 15(1), 982.

Bakardjieva M, et al. (2024) Tviblindi algorithm identifies branching developmental trajectories of human B-cell development and describes abnormalities in RAG-1 and WAS patients. European journal of immunology, 54(12), e2451004.

Gupta S, et al. (2023) Subcutaneous Immunoglobulin 16.5% (Cutaquig??) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens. Journal of clinical immunology, 43(6), 1414.

Li L, et al. (2023) Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications. BME frontiers, 4, 0019.

Rosenbach K, et al. (2023) Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment. Journal of clinical immunology, 43(5), 912.

Li Z, et al. (2023) Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases. Journal of clinical immunology, 43(8), 2127.

Eddens T, et al. (2022) Trends in Pediatric Primary Immunodeficiency: Incidence, Utilization, Transplantation, and Mortality. *The journal of allergy and clinical immunology. In practice*, 10(1), 286.

Walter G, et al. (2020) Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review. *Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology*, 16, 34.

Ji L, et al. (2019) PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC. *Scientific reports*, 9(1), 12437.

Shrestha P, et al. (2019) Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies. *The World Allergy Organization journal*, 12(10), 100068.

Barilla-LaBarca ML, et al. (2019) Common Variable Immunodeficiency: A Standardized Patient Case for Second-Year Medical Students. *MedEdPORTAL : the journal of teaching and learning resources*, 15, 10837.

Mayor PC, et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. *The Journal of allergy and clinical immunology*, 141(3), 1028.

Collins CJ, et al. (2018) Rapid Multiplexed Proteomic Screening for Primary Immunodeficiency Disorders From Dried Blood Spots. *Frontiers in immunology*, 9, 2756.

Borte M, et al. (2017) Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. *Clinical and experimental immunology*, 187(1), 146.

Ballow M, et al. (2017) Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). *The Journal of allergy and clinical immunology*, 139(6), 2007.

Rider NL, et al. (2017) Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment. *Journal of clinical immunology*, 37(5), 461.

Pasquet M, et al. (2017) A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions? *Patient preference and adherence*, 11, 1171.

Routes J, et al. (2016) Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment. *Journal of clinical immunology*, 36(5), 450.

Di Donato N, et al. (2016) Mutations in CRADD Result in Reduced Caspase-2-Mediated Neuronal Apoptosis and Cause Megalencephaly with a Rare Lissencephaly Variant. *American journal of human genetics*, 99(5), 1117.